Free Trial

Cyclacel Pharmaceuticals (CYCC) Stock Forecast & Price Target

-0.04 (-2.29%)
(As of 07/18/2024 ET)

Cyclacel Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 2 Wall Street analysts who have issued ratings for Cyclacel Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 2 analysts, 1 has given a hold rating, and 1 has given a buy rating for CYCC.

Consensus Price Target

543.27% Upside
High Forecast$11.00
Average Forecast$11.00
Low Forecast$11.00

According to the 2 analysts' twelve-month price targets for Cyclacel Pharmaceuticals, the average price target is $11.00. The highest price target for CYCC is $11.00, while the lowest price target for CYCC is $11.00. The average price target represents a forecasted upside of 543.27% from the current price of $1.71.

TypeCurrent Forecast
7/19/23 to 7/18/24
1 Month Ago
6/19/23 to 6/18/24
3 Months Ago
4/20/23 to 4/19/24
1 Year Ago
7/19/22 to 7/19/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$11.00$11.00$21.00$120.00
Forecasted Upside543.27% Upside384.58% Upside481.07% Upside997.69% Upside
Get Cyclacel Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.

CYCC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CYCC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cyclacel Pharmaceuticals Stock vs. The Competition

TypeCyclacel PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside543.27% Upside1,350.86% Upside9.06% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/3/2024Roth Mkm
1 of 5 stars
 Lower TargetBuy ➝ Buy$21.00 ➝ $11.00+384.58%
12/19/2023Brookline Capital Management
5 of 5 stars
K. Dolliver
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3 of 5 stars
 Lower TargetOutperform$150.00 ➝ $120.00+997.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:12 PM ET.

CYCC Forecast - Frequently Asked Questions

What is Cyclacel Pharmaceuticals' forecast for 2024?

According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Cyclacel Pharmaceuticals is $11.00, with a high forecast of $11.00 and a low forecast of $11.00.

Should I buy or sell Cyclacel Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last year. There is currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CYCC shares.

Does Cyclacel Pharmaceuticals's stock price have much upside?

According to analysts, Cyclacel Pharmaceuticals's stock has a predicted upside of 384.58% based on their 12-month stock forecasts.

What analysts cover Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals has been rated by research analysts at Roth Mkm in the past 90 days.

Do Wall Street analysts like Cyclacel Pharmaceuticals more than its competitors?

Analysts like Cyclacel Pharmaceuticals less than other "medical" companies. The consensus rating score for Cyclacel Pharmaceuticals is 2.50 while the average consensus rating score for "medical" companies is 2.71. Learn more on how CYCC compares to other companies.

This page (NASDAQ:CYCC) was last updated on 7/18/2024 by Staff

From Our Partners